ArticleArthritis research & therapy2025
Investigating potential biomarkers associated with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis using Mendelian randomization and transcriptomic analysis.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an autoimmune disorder characterized by multi-organ involvement. Early identification and accurate diagnosis of AAV is crucial for improving prognosis. However, research on biomarkers associated with AAV is limited. This study aimed to explore novel biomarkers for AAV through transcriptomic data analysis and Mendelian randomization (MR).
methodsAAV-related datasets (GSE104948 and GSE108109) were analyzed. Differentially expressed genes (DEGs) between AAV and normal groups were identified in the GSE104948 dataset. MR analysis was then used to investigate the causal relationship between DEGs and AAV. Genes with a significant causal relationship were selected as candidate genes for further analysis. Machine learning algorithms, ROC curve analysis, and expression evaluation were employed to screen for biomarkers. Additionally, artificial neural networks (ANNs) were constructed, enrichment analysis and immune infiltration were performed, a molecular regulatory network was established, and potential drugs were predicted. Finally, immunofluorescence assays validated the significance of these genes in renal biopsies from patients with ANCA-associated glomerulonephritis.
resultsPDK4, PSMB10 (IVW, OR > 1, P < 0.05), PPARGC1A, and FN1 (IVW, OR < 1, P < 0.05) were identified as biomarkers. Specifically, PDK4 and PPARGC1A exhibited significant down-regulation in the AAV group compared to the normal group, while FN1 and PSMB10 showed an opposite pattern. The ANN created based on biomarkers exhibited a robust predictive capacity for assessing the risk of AAV. Furthermore, co-enrichment of PDK4 and PPARGC1A was observed in 'butanoate metabolism', and 'fatty acid metabolism'. Meanwhile, there was a strong positive correlation observed between naive B cells and PDK4, while a substantial negative correlation was found with PSMB10. Molecular regulatory network results demonstrated that XIST exerted regulatory effects on PDK4, FN1, and PPARGC1A through hsa-miR-103a-3p, hsa-miR-1271-5p, and hsa-miR-23a-3p simultaneously. Besides, this study revealed that 19 drugs exhibited potential targeting capabilities towards 4 biomarkers, such as dacarbazine, dichloroacetate, and bortezomib. Validation in renal biopsies from patients with ANCA-associated glomerulonephritis confirmed decreased glomerular expression of PDK4 and PPARGC1A, and increased expression of FN1 and PSMB10 compared to controls.
conclusionPDK4, PPARGC1A, FN1, and PSMB10 were identified as biomarkers causally related to AAV, offering potential for both precise diagnosis and targeted treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.